RQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedFL
Frazier Life Sciences
Activity from announced rounds
Activity in this selectionSeries A
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $315M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionAirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosed